MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
Launched by UROLOGICAL RESEARCH NETWORK, LLC · Feb 2, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new treatment method for prostate cancer called MRI/Ultrasound Fusion Guided Laser Ablation. The goal is to see how effective this targeted laser treatment is in managing prostate cancer over time. Researchers will look at various outcomes, including any side effects from the procedure, the chances of the cancer coming back, and how the treatment affects patients' sexual and urinary functions.
To participate in this trial, men between the ages of 50 and 65 with low or intermediate-risk prostate cancer may be eligible, especially if their biopsy results show less than 50% of cancer in the prostate. Men older than 65 with similar biopsy results may also qualify. It's important that participants do not have any advanced cancer spread beyond the prostate. Throughout the trial, participants can expect regular follow-ups to monitor their health and the effectiveness of the treatment. This study aims to provide valuable information that could help improve future prostate cancer treatments.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Men between 50 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \<50% positive core rate by prostate lobe
- • Men older than 65 years of age with clinical diagnosis of prostate cancer \<50% positive core rate by prostate lobe
- • Absence of extra-capsular extension
- • Absence of seminal vesicle invasion
- • Absence of regional or distant metastatic disease
- • Multiparametric MRI of the prostate performed either before the biopsy or \>10 weeks after prostate biopsy
- • Treated with Cryotherapy of the prostate
- • Treatment based on co-registration between MP-MRI and Prostate Ultrasound
- Exclusion Criteria:
- • Prior treatment of prostate cancer in the form of surgery.
- • Performance status greater than 0 based on ECOG criteria
- • Mental status impairment
About Urological Research Network, Llc
Urological Research Network, LLC is a dedicated clinical trial sponsor specializing in advancing innovative treatments and therapies for urological conditions. With a robust commitment to improving patient outcomes, the organization collaborates with leading researchers, healthcare providers, and industry partners to conduct rigorous clinical studies. By leveraging state-of-the-art methodologies and a patient-centered approach, Urological Research Network aims to enhance the understanding of urological diseases and facilitate the development of groundbreaking solutions that address unmet medical needs in this vital field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami Lakes, Florida, United States
Patients applied
Trial Officials
FERNANDO J BIANCO, MD
Principal Investigator
UROLOGICAL RESEARCH NETWORK
EUSEBIO LUNA, MD
Study Director
UROLOGICAL RESEARCH NETWORK
Isabel H Lopez, MD
Study Director
UROLOGICAL RESEARCH NETWORK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials